Abstract
Streptococcus pneumoniae is a major cause of invasive infectious diseases. While current conjugate vaccines are effective in children, the emergence of non-vaccine serotypes necessitates broader coverage. This research explores using Pneumococcal Surface Protein A (PspA) as a carrier protein for the PS6B polysaccharide, aiming to create a vaccine with wider protection. By optimizing conjugation chemistry—specifically replacing EDAC with DMT-MM—the study achieved a significant increase in reaction yield from <10% to approximately 50%. Despite structural changes to PspA during conjugation, its immunogenicity and protective capacity remained intact, offering a promising pathway for more efficient vaccine production.
Introduction
The fight against Streptococcus pneumoniae—the pathogen responsible for pneumonia, meningitis, and sepsis—has been largely successful due to conjugate vaccines. However, these vaccines are limited by "serotype replacement," where strains not covered by the vaccine fill the ecological niche left by targeted strains. Furthermore, traditional carrier proteins like tetanus toxoid can lead to carrier-induced epitopic suppression.
This study, a Master’s thesis by Cátia Taniela Perciani conducted at the University of São Paulo and the Butantan Institute, proposes a dual-action strategy: using a native pneumococcal protein, PspA, as the carrier. PspA is highly conserved across various serotypes, potentially providing protection against a broader range of strains than polysaccharide-only vaccines.
Methodology
The research focused on the PS6B polysaccharide, a prevalent serotype in Brazil, and PspA. The primary technical challenge addressed was the efficiency of the conjugation reaction.
Conjugation Optimization
- Chemical Activator: The study compared the traditional activator EDAC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) with DMT-MM (4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride). DMT-MM was hypothesized to be more stable in aqueous environments.
- Protein Modification: To prevent unwanted self-conjugation and precipitation, the lysine groups of PspA were protected using formaldehyde.
- Spacer Evaluation: Different chemical spacers (ADH and OCT) were tested to determine the optimal distance between the protein and the polysaccharide for maintaining stability and immunogenicity.
Evaluation
The structural integrity of the modified proteins was assessed via Circular Dichroism (CD). Immunogenicity was evaluated in Balb/c mice through ELISA (antibody titers), complement deposition assays, and Opsonophagocytic Activity (OPA) assays to measure functional bacterial killing.
Results and Discussion
Breakthrough in Production Yield
The most significant finding was the impact of the activator swap. Replacing EDAC with DMT-MM increased the conjugation yield from less than 10% to roughly 50-65%. This five-fold increase represents a major advancement for the economic feasibility of vaccine manufacturing. Additionally, formaldehyde protection of lysine groups successfully prevented protein precipitation without compromising the protein's core immunological properties.
Structural vs. Functional Integrity
Circular Dichroism analysis revealed that the conjugation process altered the secondary structure of PspA, specifically reducing its alpha-helix content. However, immunological assays demonstrated that this "unfolding" did not impair the protein's ability to induce a protective immune response. The immune system effectively recognized the protein's epitopes, producing antibodies capable of triggering bacterial destruction.
Polysaccharide Immunogenicity
The study confirmed that the PS6B polysaccharide is a relatively weak antigen in the mouse model. While the conjugate vaccine induced a dose-dependent response, the titers for the sugar component were lower than those for the protein component, highlighting a persistent challenge in developing vaccines for this specific serotype.
Conclusion
This research demonstrates that optimizing the chemical "handshake" between vaccine components can drastically improve production efficiency. By utilizing DMT-MM and a native carrier protein like PspA, it is possible to create high-yield conjugate vaccines that offer potentially broader protection against S. pneumoniae. Future work will focus on using adjuvants to enhance the response to the PS6B component and developing multivalent formulations to maximize clinical impact.
Reference: Perciani, C. T. (2011). Polissacarídeo sorotipo 6B de Streptococcus pneumoniae (PS6B) e proteína de superfície pneumocócica A (PspA): métodos de conjugação e avaliação da resposta imune (Master's Thesis). University of São Paulo.
Summary updated